Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase 2a Ascending Multiple Dose Safety, Efficacy, and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Adolescents and Adults With Sickle Cell Disease

Next Previous
Trial Profile

An Open Label Phase 2a Ascending Multiple Dose Safety, Efficacy, and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Adolescents and Adults With Sickle Cell Disease

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbon monoxide (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Sponsors Hillhurst Biopharmaceuticals

Most Recent Events

  • 08 Jan 2026 Planned End Date changed from 31 Dec 2025 to 30 Jun 2026.
  • 08 Jan 2026 Planned primary completion date changed from 31 Aug 2025 to 31 Mar 2026.
  • 23 Jul 2025 According to Hillhurst Biopharmaceuticals media release, first readout expected by the end of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top